EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases

Arun Kumaran Anguraj Vadivel, Sanja Pajovic, Robert Siddaway, Sabrina Zhu, Stefanie-Grace Sbergio, Olivera Matic, Lauren Phillips, Yong Jia Bu, Mark Nitz, Cynthia Hawkins iD

Neuro-Oncology · 2025

DOI: 10.1093/neuonc/noaf033 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Neuro-Oncology, 2025. Verfasst von Arun Kumaran Anguraj Vadivel und 9 weiteren Autor:innen. Beteiligte Einrichtung: The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada. Hauptthemen laut MEDLINE: Glioma, Proteomics, Brain Neoplasms, Methyltransferases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Canadian Cancer Society Research Institute, CIHR, Canadian Institutes of Health Research.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Diffuse midline glioma (DMG) is a highly aggressive pediatric brain tumor with limited treatment options despite extensive genomic characterization. The aim of this study was to investigate the proteomic landscape of DMG to identify potential therapeutic targets.

Methods

We conducted a comprehensive proteomic analysis using LC-MS3, along with DNA methylation and DNA/RNA sequencing in 55 DMG patients’ samples. post-translational modification profiling (phosphoproteome and methylproteome) was conducted in 30 patient samples. We then investigated the effects of modulating key protein targets on protein methylation, protein synthesis, and DMG cell growth in vitro and in vivo.

Results

DMGs exhibited high global protein methylation, with significant enrichment of translation machinery proteins and factors involved in apoptosis regulation. Surprisingly, while targets of key kinases were highly phosphorylated, overall protein phosphorylation was lower in DMG compared to normal brain tissues. Non-histone methyltransferases METTL13 and METTL21B, along with protein kinases PAK2, PRKACA, and AKT1, were identified as key players in DMG methylproteome and phosphoproteome, respectively. METTL13 knockdown led to reduced EEF1A1 protein methylation, a shift in oncoprotein synthesis, and inhibited DMG cell growth in vitro and in vivo.

Conclusions

Our findings highlight the dependency of DMG on methyl-signaling pathways, particularly involving METTL13, which regulates EEF1A1 protein methylation and oncoprotein synthesis. Targeting the non-histone methyltransferases offers a promising therapeutic strategy for DMG. This study underscores the potential of post-translational modifications, specifically methyl-signaling pathways, as novel therapeutic targets for DMG and possibly other currently incurable cancers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaProteomicsBrain NeoplasmsMethyltransferasesProteomeBiomarkers, TumorHumansAnimalsDNA MethylationCell ProliferationMiceMaleFemaleTumor Cells, CulturedChildMice, NudeApoptosisChild, Preschool

Stichwörter der Autor:innen

DIPGDMGMETTL13non-histone methyltransferaseproteomics

Substanzen

MethyltransferasesProteomeBiomarkers, Tumor

Autor:innen und Institutionen

  • The Arthur and Sonia Labatt Brain Tumour Research Centre, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Division of Pathology, The Hospital for Sick Children, Toronto, Ontario, Canada.
  • Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada.
  • Department of Chemistry, University of Toronto, Toronto, Ontario, Canada.

ORCID-Profile: Cynthia Hawkins

Förderung

  • Canadian Cancer Society Research Institute
  • CIHR
  • Canadian Institutes of Health Research

Zitieren

APA

Anguraj Vadivel, A. K., Pajovic, S., Siddaway, R., Zhu, S., Sbergio, S. G., Matic, O., Phillips, L., Bu, Y. J., Nitz, M., & Hawkins, C. (2025). The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases. Neuro-Oncology. https://doi.org/10.1093/neuonc/noaf033

Vancouver

Anguraj Vadivel AK, Pajovic S, Siddaway R, Zhu S, Sbergio SG, Matic O, et al. The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases. Neuro-Oncology. 2025. doi:10.1093/neuonc/noaf033

BibTeX
@article{AngurajVadivel2025,
  author = {Anguraj Vadivel, Arun Kumaran and Pajovic, Sanja and Siddaway, Robert and Zhu, Sabrina and Sbergio, Stefanie-Grace and Matic, Olivera and Phillips, Lauren and Bu, Yong Jia and Nitz, Mark and Hawkins, Cynthia},
  title = {The proteomic landscape of diffuse midline glioma highlights the therapeutic potential of non-histone protein methyltransferases},
  journal = {Neuro-Oncology},
  year = {2025},
  doi = {10.1093/neuonc/noaf033}
}
Kostenlos starten →